Product About Pricing Support Login Sign Up
Deep Dives
Deep Dives

Speciality Medicines IPO GMP Live: Price & Review 2026

Speciality Medicines IPO GMP Live: Price & Review 2026

Speciality Medicines IPO GMP, Date, Price, Review, Details (2026)

When retail investors look at pharmaceutical IPOs, they often assume the company actually manufactures drugs. That is not always the case.

Speciality Medicines Limited (formerly known as Speciality Medicines Private Limited) is currently a marketing and distribution engine. They source finished formulations of specialty pharmaceutical products from third-party manufacturers and push them into the market.

Now, they are tapping the BSE SME platform to fund a massive pivot: building their own R&D facility and expanding into international markets like Latin America and Africa.

👉 But is a distributor transitioning into R&D a brilliant growth story, or an execution risk waiting to happen?

Here is the no-nonsense, data-backed review of the Speciality Medicines IPO.

Speciality Medicines IPO – Quick Summary

  • IPO Type: SME IPO
  • Price Band: ₹117 – ₹124
  • IPO Dates: March 20 – March 24, 2026
  • Issue Size: 23.50 Lakh Shares
  • Listing: BSE SME
  • GMP: Currently muted

👉 Key Insight: This is a 100% fresh issue IPO focused on business expansion and R&D transformation.

The Cheat Sheet: What You Need to Know

This is an SME Book Built Issue consisting entirely of fresh equity, listing on the BSE SME platform.

Feature

Details

IPO Open Date

Friday, March 20, 2026

IPO Close Date

Tuesday, March 24, 2026

Price Band

₹117 to ₹124

Total Issue Size

Up to 23,50,000 Equity Shares

Fresh Issue

100% Fresh Issue (No OFS)

Face Value

₹10 per share

Listing At

BSE SME

👉 Important: Since there is no Offer For Sale, promoters are not exiting.

Speciality Medicines IPO GMP (Grey Market Premium)

The speciality medicines limited ipo GMP is currently quiet.

Latest GMP Trend (Market-Based Insight)

  • GMP Range: ₹0 to ₹5 (indicative)
  • Sentiment: Neutral to cautious
  • Demand: Waiting for subscription data

GMP Interpretation

GMP Level

Market Signal

₹0

Weak or uncertain demand

₹5–₹15

Moderate interest

₹20+

Strong listing expectation

👉 Currently, GMP suggests wait-and-watch mode.

  • SME pharma IPOs usually perform well only if margins are sustainable
  • Aggressive pricing = weak listing
  • Fair pricing = strong HNI participation

About Speciality Medicines Limited

  • Former Name: Speciality Medicines Private Limited
  • Core Business:
    • Marketing & distribution of specialty pharma products
  • Key Strategy:
    • Transition into R&D-driven pharma company

Business Model Breakdown

Current Model:

  • Procures finished formulations
  • Distributes through network
  • Asset-light, margin-driven

Future Model:

  • Build R&D center
  • Develop own formulations
  • Expand internationally

👉 This IPO is essentially a business evolution story

The Financials: The Pre-IPO Sprint

When you strip away the marketing, you see a company that has hit the absolute accelerator in the year leading up to its IPO.

Parameter

FY 2023

FY 2024

FY 2025

Total Income

₹23.19 Cr

₹27.65 Cr

₹58.53 Cr

Profit After Tax

₹1.69 Cr

₹2.93 Cr

₹8.60 Cr

Total Borrowings

₹3.63 Cr

₹2.85 Cr

₹5.04 Cr

Net Worth

₹5.93 Cr

₹15.06 Cr

₹30.41 Cr

Financial Analysis (Deep Dive)

1. The Top-Line Explosion

  • Revenue doubled in FY25
  • Strong distribution growth

2. The Margin Machine

  • PAT margin ~14.7%
  • Extremely high for distribution

3. Balance Sheet Strength

  • Net worth doubled
  • Indicates capital efficiency

Financial Red Flag

👉 Sudden spike in revenue and profit just before IPO

This pattern is commonly observed in SME IPOs and should be analyzed carefully.

Where is the Money Going? (Objects of the Issue)

1. Building an R&D Centre (₹12.67 Cr)

  • Location: Gujarat
  • Strategic shift to product development

2. Working Capital (₹8 Cr)

  • Supports daily operations
  • Reduces dependency on debt

3. International Expansion (₹2.99 Cr)

  • Bioequivalence studies
  • Entry into LATAM & Africa

4. Marketing & Promotions (₹2 Cr)

  • Brand visibility in India

Speciality Medicines IPO Review: The Red Flags

❗ 1. Manufacturing Dependency

  • No in-house manufacturing
  • Fully dependent on third parties

❗ 2. The Execution Pivot

  • Moving into R&D is risky
  • Requires expertise + capital

❗ 3. Pre-IPO Profit Spike

  • Revenue doubled
  • Profit tripled

👉 Could be:

  • Genuine growth
  • OR pre-IPO financial dressing

Industry Comparison

Factor

Distribution Model

R&D Pharma Model

Risk

Low

High

Margin

Moderate

High

Entry Barrier

Low

Very High

Capital Requirement

Low

High

👉 Speciality Medicines is shifting from low-risk to high-risk, high-reward model

  • SME IPO subscription rates crossing 50x–200x in strong cases
  • Pharma IPOs gaining traction due to:
    • Export demand
    • Specialty drugs growth
  • Investors focusing on:
    • Profit sustainability
    • Margin quality

Expert IPO Analysis 

Based on similar SME pharma IPOs:

Winning Factors:

  • Consistent earnings
  • Strong GMP
  • Clear business model

Risk Factors:

  • Sudden financial spike
  • Aggressive expansion
  • Weak promoter track record

👉 Speciality Medicines falls into a high-risk, high-reward category

The Verdict

Speciality Medicines Limited is a high-margin distribution player attempting to transform into a pharma R&D company.

🟢 Bull Case

  • Strong FY25 performance
  • High margins
  • No OFS (promoters confident)
  • Global expansion potential

🔴 Bear Case

  • Execution risk
  • Dependency on suppliers
  • Financial spike concerns

Should You Apply for Speciality Medicines IPO?

✅ Apply If:

  • You want SME IPO exposure
  • You understand high-risk bets
  • You aim for listing gains

❌ Avoid If:

  • You prefer stable companies
  • You are long-term conservative investor

How to Apply for Speciality Medicines IPO (Step-by-Step)

You can apply using a trusted platform like Firstock – a SEBI registered discount broker.

Why Firstock?

  • ₹0 brokerage on delivery
  • ₹20 flat per order
  • Easy IPO application
  • Beginner-friendly app

👉 Makes IPO investing simple and cost-efficient

Final Conclusion

The Speciality Medicines IPO is not just another SME listing — it’s a business transformation story.

👉 If execution succeeds → massive upside potential

👉 If execution fails → serious downside risk

Smart Investor Strategy:

  • Track GMP daily
  • Watch subscription data
  • Avoid blind investing

FAQs

1. What is Speciality Medicines IPO GMP today?

Currently, GMP is ₹0–₹5, indicating neutral sentiment.

2. Is this IPO SME or Mainboard?

This is an SME IPO listed on BSE SME platform.

3. What does Speciality Medicines Private Limited do?

It operates as a pharma distributor, planning to move into R&D and manufacturing.

4. Is there any OFS in this IPO?

No, it is a 100% fresh issue.

5. Is this IPO good for listing gains?

Depends on:

  • GMP trend
  • Subscription levels
  • Pricing

6. What are the major risks?

  • Execution risk
  • Supplier dependency
  • Financial sustainability

7. What is the lot size?

Typically higher for SME IPOs (~₹2 lakh investment).

Disclaimer

Investments in securities markets are subject to risks. Read all IPO documents carefully before investing.

Source: Draft Red Herring Prospectus (DRHP) of Speciality Medicines Limited.

Read next

Footer

Take control of your wealth with Firstock. Track your investments, trade wisely—all in one easy-to-use platform.

Download the App now

Invest in Stocks, Mutual Funds, IPOs, Bonds, ETFs & Futures, Options,

Company

About Us Product Pricing Company Profile Become a Partner Contact Us

Offerings

Stocks & ETF - G(Sec) Future & Options Gold Bonds & Govt. Sec Mutual Funds IPO Developers API

Support

Account Opening Fund Transfer List of Charges Downloads Support Portal Raise a Ticket

Utilities

Brokerage Calculator Margin Calculator Margin Approved Securities Notice Board Holiday Calendar Referral Programme

© 2025 Firstock. All rights reserved.

Firstock Broking Pvt Ltd

  • No 350,1st Floor, 36th A Cross 7th Main Rd 5th Block Jayanagar, Bengaluru, KA 560041.
  • NSE​ &​ BSE – SEBI Registration No.: INZ000260334
  • CDSL: Depository services – SEBI Registration No.: IN-DP-67-2015 Mutual Fund ARN: 132812

    • For any complaints pertaining to securities broking please write to [email protected] for DP related to [email protected] Please ensure you carefully read the Risk Disclosure Document as prescribed by SEBI.

    Attention Investors:

    Investments in the securities market are subject to market risks. Please read all related documents carefully before investing.

    Prevent Unauthorized Transactions in Your Trading/Demat Account:
    Update your mobile number and email ID with your stock broker or depository participant. Receive alerts and information about your transactions on your registered mobile number/email for all debit and other important transactions in your trading/demat account directly from the Exchange/CDSL on the same day.

    KYC is a one-time exercise while dealing in the securities market.
    Once KYC is completed through a SEBI-registered intermediary (broker, DP, mutual fund, etc.), you do not need to undergo the same process again when approaching another intermediary.

    No need to issue cheques when subscribing to an IPO.
    Simply write your bank account number and sign the application form to authorize your bank to make the payment in case of allotment. There is no worry about refunds, as the money remains in the investor's account.

    Procedure to file a complaint on SCORES (Easy & Quick): Register on the SCORES portal and keep the following mandatory details ready: Name, PAN, Address, Mobile Number, and Email ID.

    Benefits: Effective communication and speedy redressal of grievances.{" "}

    Dear Investor,

    If you are subscribing to an IPO, there is no need to issue a cheque. Please write your bank account number and sign the IPO application form to authorize your bank to make the payment in case of allotment. In case of non-allotment, the funds will remain in your bank account. As a business, we do not provide stock tips and have not authorized anyone to trade on behalf of others.

    Important:

    Stock brokers can accept securities as margin from clients only by way of a pledge in the depository system w.e.f. September 1, 2020.

    Update your email ID and mobile number with your stock broker or depository participant and receive OTPs directly from the depository on your registered email ID and/or mobile number to create pledges.

    Check your securities, mutual funds, and bonds in the consolidated account statement issued by NSDL/CDSL every month.

    Disclaimer:

    The Stock Exchange, Mumbai, is not in any manner answerable, responsible, or liable to any person for any acts of omission or commission, errors, mistakes, and/or violations—actual or perceived—by us or our partners, agents, associates, etc., of any rules, regulations, by-laws of the Stock Exchange, SEBI Act, or any other laws in force from time to time.

    The Stock Exchange, Mumbai, is not responsible or liable for any information on this website or for any services rendered by our employees or representatives. Please refer to BSE compliance for more details.

    Investor Alert:

    Investors are requested to note that stock broker Firstock Broking Private Limited (Firstock) is permitted to receive/pay money from/to investors only through designated bank accounts, named as "client bank accounts."

    Firstock is also required to disclose these client bank accounts to the Stock Exchange.

    Hence, you are requested to use only the following client bank accounts for any transactions in your trading account with us. The details of these accounts are also displayed by the Stock Exchanges on their website under “Know / Locate Your Stock Broker.”

    Terms & Conditions Policies & Procedures Investor Grievance Privacy Policy Disclosure Investor Charter PMLA Policy Investor’s Attention SEBI - Investor website Investor Education & Awareness E-Voting NSE BSE CDSL KYC Status SEBI SCORES Policy of Handling Good-Till-Trigger Orders Smart Online Dispute Resolution